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This is in response to the article “Cancer-related fa-
tigue: a review”, published in April 2011 by Campos et 
al.1. We have a few concerns regarding certain statements 
made by the authors. 
The advances in oncology have rendered cancer from 
a universally lethal disease to a chronic condition for 
many and a curable illness for a few. Hence, the potential 
long-term adverse effects of supportive care interventions 
should be given due consideration.
Though the authors have mentioned the efficacy of 
amphetamines such as methylphenidate/dexmethylpheni-
date, no mention was made on the potential risks involved, 
such as the risk of addiction, increased blood pressure, car-
diovascular risks, hyperthermia, muscle catabolism etc2. 
Given that cancer patients are expected to survive longer 
due to the improvements in oncology, we should exercise 
caution against the use of drugs with potential for abuse in 
cancer patients who are expected to survive for long peri-
ods. Regarding their statement that modafinil is effective 
only in patients with severe fatigue, we would like to state 
that there is no uniform consensus as to how fatigue can be 
graded as mild, moderate, and severe. Different scales ex-
ist, such as the Brief Fatigue Inventory, the Fatigue Severity 
Index etc. Scoring patterns are different and hence severity 
can vary with the questionnaire used. Moreover, modafinil 
is said to benefit patients with both moderate and severe 
fatigue3 (rather than only severe fatigue). Modafinil can be 
especially beneficial in certain subsets of cancer patients, 
such as patients on radiation therapy (RT), since patients 
on RT are more likely to develop cancer-related fatigue 
at higher incidences and higher magnitudes when com-
pared to cancer patients that are not on RT4,5. We opine 
that modafinil would be a better choice when compared 
to methylphenidate/dexmethylphenidate because of the 
lesser addictive potential and lower risk of toxicities.
We suggest that the use of erythropoiesis stimulating 
agents (ESA) such as erythropoietin and darbopoetin in 
patients with hemoglobin level < 10 mg/dL can be more 
dangerous compared to routine measures, such as the use 
of hematinics and blood transfusions, especially in patients 
who are on radical curative treatments with chemothera-
py or radiotherapy. Not only do ESAs increase the risk of 
thromboembolisms, but also being growth factors, they 
may promote tumor growth and progression and hence 
may offset benefits of chemotherapy and radiotherapy. We 
suggest that ESAs should be reserved for terminally ill pa-
tients only.
We have minor concerns regarding the use of guarana. 
Since guarana extracts may work in a way similar to caf-
feine, we suggest that it may be used only after it has been 
tested for cardiovascular side effects, such as arrythmias6, 
in a large population. 
We are, however, very appreciative of the overall mes-
sage of the article by Campos et al.1, since it highlights a 
very important and often neglected topic.
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